Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
EKLF/KLF1 CRISPR/Cas9 KO Plasmid (h): sc-402366
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- EKLF/KLF1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the EKLF/KLF1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EKLF/KLF1 CRISPR/Cas9 KO Plasmid (h) | sc-402366 | 20 µg | $397.00 |
Overview
KLF1 (erythroid Krüppel-like factor; EKLF) is a zinc-finger transcription factor that functions as a master regulator of erythroid lineage commitment and terminal red blood cell maturation. It binds CACCC motifs to control erythroid-specific gene expression programs, including globin gene regulation, hemoglobin synthesis, membrane/cytoskeletal remodeling, and coordination of enucleation-associated pathways. KLF1 interfaces with chromatin and transcriptional machinery to shape erythroid differentiation states and metabolic adaptation during erythropoiesis. Genetic perturbation or dysregulated expression of KLF1 is linked to inherited red blood cell phenotypes and hemoglobin switching defects, supporting its relevance in studies of anemia-related mechanisms and erythroid developmental biology.
EKLF/KLF1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KLF1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KLF1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KLF1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish EKLF/KLF1 protein expression.
This CRISPR knockout system enables efficient generation of KLF1-deficient cell models for investigation of EKLF/KLF1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KLF1 exon(s) critical for EKLF/KLF1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KLF1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by EKLF/KLF1 CRISPR/Cas9 KO Plasmid (h) and EKLF/KLF1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KLF1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by EKLF/KLF1 HDR Plasmid (h) and EKLF/KLF1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KLF1 homology arms to support homology-directed repair at defined KLF1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.